

RESEARCH ARTICLE

Open Access

Effect of a DIVA vaccine with and without in-feed use of coated calcium-butyrate on transmission of *Salmonella* Typhimurium in pigs

Lotte De Ridder^{1,4*}, Dominiek Maes⁴, Jeroen Dewulf⁴, Frank Pasmans⁵, Filip Boyen⁵, Freddy Haesebrouck⁵, Estelle Méroc¹, Stefan Roels², Bregje Leyman⁵, Patrick Butaye^{3,5} and Yves Van der Stede^{1,6}

Abstract

Background: For satisfactory *Salmonella* control, good biosecurity along the pork production chain is crucial, although additional control measures on-farm need to be considered. This study evaluated the effect of two potential control measures against the spread of *Salmonella* Typhimurium via a transmission experiment with 56 piglets (3–15 weeks of age): two groups were orally vaccinated with 10^7 - 10^8 Colony Forming Units (CFU)/2 mL of a new attenuated *Salmonella* Typhimurium vaccine 'Salmoporc- Δ rfa' with DIVA capacities (Differentiation between Infected and Vaccinated Animals) ($n = 2 \times 16$); the feed of one group was additionally supplemented with coated calcium-butyrate salt. Two weeks post vaccination, four pigs per group were orally challenged with 10^7 CFU/2 mL of a *Salmonella* Typhimurium strain 112910a. Both groups were compared with a positive (challenged/untreated; $n = 16$) and negative (unchallenged/untreated; $n = 8$) control group. Until six weeks post challenge, blood, individual faecal and finally tissue samples were examined. Adjusted transmission ratios 'R_a' were estimated, based on the challenge strain isolation from faecal and/or tissue samples.

Results: In both intervention groups, R_a values were lower compared to the positive control group, although these differences were not significant. In the combination group DIVA vaccine + coated butyrate, less non-challenged contact animals excreted *Salmonella* and less tissue samples were found *Salmonella*-positive in all pigs, when compared to the positive control group ($P < 0.01$). Seroconversion was detected in none of the vaccinated animals before challenge, when using a commercial lipopolysaccharide (LPS) ELISA targeting only *Salmonella* O-antigens, deleted in this vaccine. This was in contrast with an in-house whole-cell ELISA testing for various *Salmonella* antigens, in which *Salmonella*-specific antibodies were found pre-challenge in the serum of the vaccinated pigs.

Conclusions: Both interventions showed a limited, non-significant reduction of *Salmonella* transmission between piglets. They may have applications towards *Salmonella* control and surveillance. Firstly, the number of *Salmonella* excreting contact pigs was significantly lower in the group where vaccination was combined with coated calcium-butyrate salt in the feed; secondly, the new vaccine confirmed its DIVA capacity. Therefore, these interventions merit further research with larger sample sizes, to optimize their use for *Salmonella* programmes.

Keywords: *Salmonella* Typhimurium, Pig, DIVA vaccine, Coated calcium-butyrate salt, Transmission

* Correspondence: lotte.deridder@ugent.be

¹Unit of Co-ordination in Veterinary Diagnostics-Epidemiology and Risk Analysis, CODA-CERVA, Groeselenberg 99, 1180 Ukkel, Belgium

⁴Department of Obstetrics, Reproduction and Herd health, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820 Merelbeke, Belgium

Full list of author information is available at the end of the article

Background

Salmonella infections are one of the most important and widely distributed foodborne diseases in the European Union. Contaminated pork has been linked to 34.5% of the human outbreaks of *Salmonella enterica* subspecies *enterica* serovar Typhimurium (*Salmonella* Typhimurium) in the EU [1]. Therefore, any reduction of the *Salmonella* risk by pork products would contribute to the protection of human health. However, the control of *Salmonella* in pork production remains a significant challenge in the preharvest sector. Implementing good biosecurity and operating a high standard of hygiene is crucial in every link of the pork production chain [2], but additional control measures on-farm are indispensable [3].

Vaccination is one possible supplementary measure that can be implemented in *Salmonella* control programmes. It is currently used successfully in the poultry industry of several European countries [4,5]. Also in pigs, various vaccine studies have demonstrated a significant decrease in clinical signs and excretion of *Salmonella* [2,6-8]. Most European serosurveillance programmes however, rely on commercial lipopolysaccharide (LPS) ELISAs, which do not allow differentiation between *Salmonella*-specific antibodies induced by vaccination or by infection [9]. Several DIVA vaccines (Differentiation of Infected and Vaccinated Animals) have recently been developed [10,11], of which one vaccine, a *Salmonella* Typhimurium strain without the '*rfa*' gene, induces antibodies undetectable with LPS ELISA [11]. Another control measure with promising features against *Salmonella* infections, is the oral administration of butyrate, especially in its coated form [12,13]. Not only does this organic acid enhance pig performance by improving gut function, it also down-regulates *Salmonella* virulence gene expression [14]. None of these studies

however, have investigated the effect on the actual transmission rate of *Salmonella* between pigs.

The aim of the present study was to evaluate the effect of a commercial vaccine that was modified to a DIVA vaccine strain, and its combination with coated calcium-butyrate salt in the feed on the transmission of *Salmonella* Typhimurium in weaned pigs.

Methods

Study design

At three weeks of age, 56 *Salmonella*-negative piglets were randomly assigned to four different stables in the experimental animal facilities of CODA-CERVA, with two separated pens each (Table 1). Group A ($n = 2 \times 8$) was orally vaccinated at four and seven weeks of age with $10^7 - 10^8$ Colony Forming Units (CFU)/2 mL of a live LPS-mutant *Salmonella* Typhimurium strain, named the '*Salmoporc-Δrfa*' strain, in reference to the deletion of the '*rfa*' gene [11] in a commercial vaccine (Salmoporc®, IDT Biologika); group B ($n = 2 \times 8$) was vaccinated similarly and received additionally feed supplemented with 0.3% coated calcium-butyrate salt throughout the experiment (Globamax Performant, Sanluc International); a positive control group C (challenged/untreated; $n = 2 \times 8$) and a negative control group D (unchallenged/untreated; $n = 8$) were included as well. Each group, except the negative control group, consisted of two replicates to increase the power of the experiment.

The pens were separated with solid concrete partitions and had a semi-solid concrete floor (half grid, half rubber mats). The pig stocking density was 0.42 m² per animal. In all groups, the same starter and pig meal without antimicrobials was administered throughout the study, (*i.e.* from arrival in the experimental facilities at three weeks of age until euthanasia at 15 weeks of age), except

Table 1 Design of the transmission study with the samples/actions and diagnostics/products, as a function of the pigs' age

Age of the pigs in weeks	Sampling or action (Group)	Frequency (Number of pigs)	Diagnostic method or product
3 - 8	Floor faeces (group A, B, C, D)	Once/week (1 pool/pen; $n = 7$)	Isolation (ISO 6579 Annex D)
9 - 15	Rectal faeces (group A, B, C, D)	Twice/week (individually; $n = 56$)	Isolation (ISO 6579 Annex D)
3 - 15	Blood (group A, B, C, D)	Once/week ($n = 56$)	ELISA ^a
3 - 15	Feed supplementation (group B)	<i>Ad libitum</i> ($n = 15$)	Coated calcium-butyrate salt (Globamax Performant; Sanluc International)
4 + 7	Oral vaccination (group A, B)	Twice: primer + boost ($n = 16$ (A); $n = 15$ (B))	$10^7 - 10^8$ CFU of DIVA vaccine ' <i>Salmoporc-Δrfa</i> '
9	Oral challenge (group A, B, C)	Once; in a separate stable, with replacement 24 h later (2 pigs/pen; $n = 12$)	10^7 CFU of nalidixic acid-resistant <i>Salmonella</i> Typhimurium strain 112910a
15	Rectal faeces, Ileum + content, Caecum + content, Ileocaecal Lnn, Tonsils (group A, B, C, D)	At necropsy ($n = 56$)	Isolation (ISO 6579 Annex D)

^aTwo ELISA tests were performed: (1) commercial HerdChek Swine *Salmonella* (IDEXX); (2) In-house whole-cell ELISA (Leyman et al., 2011).

in group B for which the feed was supplemented as described above. The pigs were housed at natural day-night rhythm with *ad libitum* access to water and feed. Each group of eight pigs was provided with a rubber ball as environmental enrichment.

With the exception of the negative control group, two pigs per pen were orally challenged at nine weeks of age with 10^7 CFU/2 mL of a nalidixic acid-resistant *Salmonella* Typhimurium strain 112910a [15] in a separate pen. Twenty-four hours later, these challenged 'seeder' pigs were replaced with the naive, non-challenged contact pigs (0 Days Post Contact or 'DPC'), and all pigs were monitored until 15 weeks of age (42 DPC). This day (0 DPC) was considered as the start of the transmission experiment. Before challenge at nine weeks of age, individual blood samples and pooled faecal pen samples were taken once a week. After challenge, blood samples were obtained once a week, whereas individual rectal faeces were collected twice a week from all pigs. At necropsy, rectal faeces, ileum, ileal content, caecum, caecal content, ileocaecal lymph nodes and tonsils were sampled. The experimental design was approved by the Animal Care and Ethical Committee of the IPH-VAR (Approval number 100412-02).

Sample analysis

All faecal samples were examined using the ISO 6579 Annex D method [16]. Firstly, the samples were diluted 1:10 in buffered peptone water (BPW, Bio-Rad) and aerobically incubated for 16-20 h at 37°C. Of this solution, 0.1 mL was inoculated on a modified semi-solid Rappaport-Vassiliadis plate (MSRV, Bio-Rad) (one sample per plate) and aerobically incubated for 46-50 h at 41°C. After this period, a loopful of the growth area in this MSRV enrichment must be plated out on a xylose lysine deoxycholate agar plate (XLD, Bio-Rad) and another agar for choice. In this study was opted for a brilliant green agar plate (BGA, Lab M), known to allow satisfactory growth of both the vaccine and challenge strain. The latter plate was supplemented with 20 µg/mL nalidixic acid for differentiating these *Salmonella* Typhimurium strains. For 21-27 h, both plates were given an aerobic incubation at 37°C. A *Salmonella*-suspected colony on the BGA plates was expected to be only the nalidixic acid-resistant challenge strain, whereas on the XLD plates, colonies of both the challenge and vaccine strain were able to grow. From these XLD or BGA plates, one *Salmonella*-suspected colony was inoculated in triple sugar iron agar (TSI, Bio-Rad) and lysine decarboxylase bouillon (Oxoid) and incubated for 18-24 h at 37°C for final confirmation. After preparation, the tissue samples were investigated similarly to the faecal samples.

The blood samples were allowed to coagulate at room temperature and were then centrifuged for 15 min at 1200g. The serum collected thereafter, was diluted twenty-fold and analysed with two ELISA tests: (1) a

commercial ELISA kit based on LPS O-antigens of serogroup B, C1 and D (HerdChek Swine *Salmonella*, IDEXX); (2) an in-house whole-cell ELISA, based on a variety of surface-antigens on the *Salmonella* Typhimurium strain 112910a [11]. Consequently, antibodies against the '*Salmporc-Δrfaj*' vaccine strain, which expresses no O-antigens, should only be detectable with this whole-cell ELISA. Other *Salmonella* strains on the other hand, will be detected in both ELISA tests. Optical densities (OD) in both ELISAs were determined by photo spectrometry with a 650 nm filter. Samples with a Sample-to-Positive (S/P) ratio ≥ 0.25 (= OD% ≥ 10) were defined as positive.

Statistical analysis

Based upon all faecal samples, the numbers of excreting pigs were compared via generalized estimating equations (GEE), using the proc genmod procedure in SAS 9.2 (SAS Institute Inc., USA). For this, a binomial distribution and logit link function were used. Bacteriological results from the tissue samples (ileum, ileal content, caecum, caecal content, ileocaecal lymph nodes, tonsils) were compared between groups (DIVA vaccine, DIVA vaccine + Coated Butyrate, Positive Control) using logistic regression analysis in SAS 9.2. *P*-values below 0.05 were considered significant.

The transmission of *Salmonella* Typhimurium in each group was estimated on the basis of the stochastic 'SI' infection model (Susceptible-Infectious), using an 'adjusted' transmission ratio ' R_a ' for the observed period of six weeks, which is derived from the basic reproduction ratio R_0 for the entire infectious period [17]. In this study, each intervention group contained $n = 8$ piglets, of which initially two challenged animals were infectious ($I_0 = 2$) and six contact animals were susceptible ($S_0 = 6$). An R_a value below or above one means respectively, that each infected animal will pass the infection on to less or more than one naive contact animal during the observed period of six weeks. This R_a value was estimated via the Maximum Likelihood Estimation (MLE) based on the final size of the study, which represents the total number of contact infections [18]. A contact animal was considered infected, when at least one sample was positive in: i) individual faeces, or ii) ileum, caecum and/or their content, or iii) ileocaecal lymph nodes and/or tonsils, or iv) all tissues and/or all faeces collected. R_a values were calculated for each of the previous four categories, and significant differences between groups were assessed [19].

Results

Bacteriological examination

In each group, all pooled faecal samples taken prior to challenge were *Salmonella*-negative. All individual faecal samples from the negative control group remained negative during the whole experiment. One contact pig of group B

died at -1 DPC due to a polybacterial bronchopneumonia and was excluded from the study (no respiratory pathogens could be identified at necropsy).

After challenge, no significant differences between the groups were observed in the numbers of *Salmonella*-excreting animals, when considering all challenged and non-challenged pigs (Figure 1). If the challenged seeder pigs were not taken into account for all 11 sampling points however, significantly fewer *Salmonella*-positive samples were obtained in group B (9/121), when compared to group C (30/132) ($P < 0.01$). At the end of the trial, respectively 8/12 (67%), 7/11 (64%) and 12/12 (100%) non-challenged contact pigs from group A, B and C had excreted *Salmonella* in their feces on at least one sampling occasion (Additional file 1: Table S1). From all necropsy samples of both challenged and non-challenged pigs, 27, 13 and 41% were found positive for the challenge strain in group A, B and C, respectively, with a significant difference between group B and C ($P < 0.01$) (Table 2). Respectively 6/12 (50%), 2/11 (18%) and 10/12 (83%) non-challenged contact pigs from group A, B and C had one tissue sample or more colonized with *Salmonella*. Both the faecal shedding and tissue colonization are presented individually in Additional file 1: Table S1.

The adjusted transmission ratios R_a , based on the faecal and/or tissue results of all challenged and non-challenged pigs, were lower in all four categories in both vaccinated groups A and B, when compared to the unvaccinated group C (Table 3). These differences between groups were not significant ($P > 0.05$).

Serological examination

In the commercial LPS-ELISA, all pigs were seronegative for *Salmonella*-specific antibodies before challenge

(Figure 2). In contrast, the in-house whole-cell ELISA showed that the mean S/P ratio increased already one week before challenge in both vaccinated groups A and B, whereas the increase occurred two weeks after challenge in the positive control group C (results not shown).

Discussion

The increase of global meat consumption during the next decades is expected to be largely due to increases in pork [20]. The reduction of any pig-related public health risk is therefore of considerable importance. *Salmonella* Typhimurium represents a most relevant pig-associated risk despite current control measures [1], and was therefore selected for the present transmission experiment in weaned pigs. This study aimed to assess the effect of a DIVA vaccine [11], with and without coated calcium-butyrate salt in the feed.

As a consequence of the study design (transmission experiment), in which the treatment was applied to all pigs before challenge, the combined treatment effect on both the excretion of the inoculated pigs and the susceptibility of the contact animals is evaluated. This is an important difference with efficacy studies in which mainly the susceptibility is assessed and not the combined effect [6,21,22]. This study concept also allows to better simulate the field situation, namely infection of a treated pig which may subsequently infect other treated pigs in the area. Several other bacterial diseases have been investigated in similar experiments [18,23-30]. As the R_a values were higher than one in this experiment, the present interventions will not eradicate infection with *Salmonella* Typhimurium during the studied period. However, the treated groups demonstrated non-significantly lower R_a




Figure 1 Proportion of *Salmonella* challenge strain positive faecal samples per groups, as a function of time (DPC: days post contact). (■) DIVA vaccine; (●) DIVA vaccine + Coated calcium-butyrate salt; (x) Positive Control; (*) Negative Control. DPC = -1: Replacement and oral challenge with 10^7 CFU/2 mL *Salmonella* Typhimurium of 2 seeder pigs per group of 8 pigs, with reintroduction of seeders in their original pen 24 h later.

Table 2 Results of the descriptive and logistic regression analysis of the necropsy samples positive for the *Salmonella* challenge strain in the three groups

Group [§]	Parameters	Different necropsy samples						All necropsy samples
		Ileum	Ileal Content	Caecum	Caecal Content	Ileocaecal Lnn	Tonsils	
A) DIVA vaccine (n = 16)	Number	4 ^a	4 ^{ab}	6 ^a	5 ^{ab}	3 ^a	4 ^a	26 ^{ab}
	(Proportion)	(25%)	(25%)	(38%)	(31%)	(19%)	(25%)	(27%)
	OR*	0.67	0.21	2.23	0.23	0.49	0.25	0.55
	P-value	0.66	0.10	0.38	0.07	0.41	0.18	0.05
B) DIVA vaccine + Coated Butyrate (n = 15)	Number	2 ^a	1 ^a	2 ^a	3 ^a	1 ^a	3 ^a	12 ^a
	(Proportion)	(13%)	(7%)	(13%)	(20%)	(7%)	(20%)	(13%)
	OR*	0.25	0.03	0.34	0.12	0.15	0.14	0.30
	P-value	0.18	0.01	0.33	0.02	0.10	0.08	<0.01
C) Positive control (n = 16) (ref)	Number	5 ^a	8 ^b	4 ^a	10 ^b	5 ^a	7 ^a	39 ^b
	(Proportion)	(31%)	(50%)	(25%)	(63%)	(31%)	(44%)	(41%)

^{a, b}Numbers in a column, not sharing the same letters in superscript, are significantly different: ileal and caecal content ($P < 0.02$) and all necropsy samples ($P < 0.01$).

*Odds Ratios (OR) >1 or <1 , define the intervention of group A or B as a risk or protective factor, respectively, for having *Salmonella*-positive tissue samples, when compared to the positive control group.

[§]A) oral vaccination at four and seven weeks of age with $10^7 - 10^8$ CFU/2 mL of the live 'Salmoporc- $\Delta rfaJ$ ' strain; B) vaccination of (A) plus feed supplemented with 0.3% coated calcium-butyrate salt; C) positive control that was challenged without being treated.

values for every matrix, in comparison with the positive control group. Therefore, a more distinct reducing effect might be expected when observing pigs for a longer time, as was demonstrated in previous efficacy studies [7,31,32], which investigated the efficacy of vaccination, acidified drinking water, and fermented liquid feed during the entire finishing period, respectively. This expected enlarged difference between groups might be explained by a prolonged potential spread of *Salmonella* in the untreated control group, while no further spread is expected in the treatment groups.

Concerning vaccination, different studies have demonstrated a reduction of *Salmonella* shedding and/or *Salmonella* seroprevalence in pigs [6,7,10,33,34]. Vaccine-induced antibodies should be distinguishable however, from those induced by infection in order not to hamper

monitoring programmes based on serology. Selke *et al.* [10] developed a DIVA vaccine of which the induced antibodies were not detectable in their in-house ELISA, but the DIVA vaccine of Leyman *et al.* [11] induced antibodies undetectable with a commercial LPS ELISA that is commonly used in serosurveillance programmes (HerdChek Swine *Salmonella*, IDEXX). Consequently, the latter vaccine would be suitable for use in European serosurveillance programmes, whereas the first vaccine would not. In the present study, the method of Leyman *et al.* [11] was therefore applied on the commercial vaccine Salmoporc[®], resulting in the 'Salmoporc- $\Delta rfaJ$ ' strain. The commercial vaccine Salmoporc[®] has proven its effectiveness previously [33] using the same administration procedure as the current study, and Leyman *et al.* [11] demonstrated a similar protection after immunization with either a wild-

Table 3 Adjusted reproduction ratio R_a [95% confidence interval] for groups A, B, C, as a function of four different categories

Group [§]	Individual faeces ^a	Ileum/content/Caecum/content ^a	Ileocaecal Lnn/tonsils ^a	All tissues/individual faeces ^a
A) DIVA vaccine (n = 16)	1.76 [1.02; 9.01]	1.03 [0.56; 3.95]	0.77 [0.35; 3.80]	2.37 [1.46; 10.02]
B) DIVA vaccine + Coated Butyrate (n = 15)	2.52 [0.99; 9.62]	0.50 [0.17; 5.82]	0.37 [0.14; 4.64]	2.52 [0.99; 9.62]
C) Positive control (n = 16) *	$+\infty$ [1.88; $+\infty$]	2.52 [1.02; 9.01]	1.19 [0.70; 7.18]	$+\infty$ [1.88; $+\infty$]
P-value (A, C)	0.22	0.25	0.21	0.37
P-value (A, B)	0.47	0.38	0.21	0.27
P-value (B, C)	0.19	0.31	0.07	0.19

^aUsing the ISO method 6579 Annex D, a pig was considered as infected, if at least one of the samples of four marked categories in every column was found positive during the transmission period.

[§]A) oral vaccination at four and seven weeks of age with $10^7 - 10^8$ CFU/2 mL of the live 'Salmoporc- $\Delta rfaJ$ ' strain; B) vaccination of (A) plus feed supplemented with 0.3% coated calcium-butyrate salt; C) positive control that was challenged without being treated.

* $+\infty$ = plus infinity.




Figure 2 Weekly detection (LPS ELISA, IDEXX) of *Salmonella*-specific antibodies (mean S/P ratio), as a function of time (DPC: days post contact). (■) DIVA vaccine; (●) DIVA vaccine + Coated calcium-butyrate salt; (x) Positive Control; (*) Negative Control. DPC = -1: Replacement and oral challenge with 10^7 CFU/2 mL *Salmonella* Typhimurium of 2 seeder pigs per group of 8 pigs, with reintroduction of seeders in their original pen 24 h later.

type *Salmonella* Typhimurium strain or its DIVA variant. Therefore, the ‘Salmoporc- Δrfa ’ strain used in this study was expected to have the same protective effect as the Salmoporc[®] parent strain. Whereas the in vivo study of Leyman *et al.* [11] involved four unchallenged vaccinated piglets, this new DIVA strain was evaluated in 16 challenged piglets. Although the ‘Salmoporc- Δrfa ’ strain as single intervention resulted in a limited non-significant reduction of transmission, serological surveillance using the commercial ELISA-tests remains applicable. Therefore, it may be considered a promising tool in future *Salmonella* surveillance, worthy of further investigation for optimization.

Previous studies with organic acids in the feed showed both reducing [22,35] and non-reducing [36,37] capacities on *Salmonella* excretion or antibody induction. In this study, we opted for supplementing the feed with coated calcium-butyrate, as earlier studies [12,13] have shown that coating of fatty acids is needed to let them reach the colonization sites (ileum, caecum and colon) in their active form. In addition, the in-feed coated butyrate was combined with the current DIVA vaccine, as these two control strategies are believed to be complementary. Namely, both strategies have a different working mechanism to combat *Salmonella* transmission, *i.e.* the vaccination enhancing the host’s immune response and the coated butyrate targeting *Salmonella* bacteria in the gut environment and improving intestinal epithelial growth. In the current study, *Salmonella* transmission in the DIVA vaccine + butyrate group was not significantly different from the one in both other challenged groups. However, in this group significantly less non-challenged contact animals excreted *Salmonella* and significantly less organ samples of all challenged and non-challenged

pigs were found *Salmonella*-positive, when compared to in the positive control group. An additional beneficial effect was thus observed in the combination group, in comparison with the DIVA vaccine intervention on its own, which might be explained by this dual approach to *Salmonella* infection. However, the combination of both strategies would also incur considerable additional costs, in comparison with the single interventions. Therefore, more research including a cost-benefit analysis and while observing pigs for a longer period (*e.g.* from weaning till market age), is warranted.

Conclusions

Both interventions in this study did not show a significant reduction of *Salmonella* Typhimurium transmission. Significantly less contact pigs excreted *Salmonella* however, in the group where vaccination was combined with coated butyrate in the feed, and the vaccine itself confirmed its ‘DIVA’ capacity. Therefore, these interventions merit further research to improve their applicability in *Salmonella* control programmes.

Additional file

Additional file 1: Table S1. Presentation of the individual *Salmonella*-positive faecal and necropsy samples (grey) per sampling occasion and tissue, respectively.

Abbreviations

BGA: Brilliant green agar; BPW: Buffered peptone water; CFU: Colony forming units; DIVA: Differentiation between infected and vaccinated animals; DPC: Days post contact; ELISA: Enzyme-linked immuno sorbent assay; GEE: Generalized estimating equations; Lnn: Lymph nodes; LPS: Lipopolysaccharide; MLE: Maximum likelihood estimation; MSRV: Modified semi-solid rappaport-vassiliadis; OD: Optical density; S/P

ratio: Sample-to-positive ratio; TSI: Triple sugar iron; XLD: Xylose lysine deoxycholate.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

DM, JD, PB and YvDs all participated in the design and coordination of the study. All authors helped to draft the manuscript. BL provided the vaccine strain and the whole-cell ELISA. LDR carried out the herd screening, vaccination and sampling, performed the bacteriological isolation and serological assays, participated in the statistical analysis. SR, EM and YvDs helped performing the necropsy. YvDs and JD performed the statistical analysis. All authors read and approved the final manuscript.

Acknowledgements

We thank the Federal Public Service of Health, Food Chain Safety and Environment for the funding of this project (RT-09/05). The assistance in sampling of W. Van Campe and the technicians of the experimental centre is gratefully appreciated, as is the help of H. Vander Veken, A. Lucchina, F. Crombé, W. Vanderhaeghen, and L. Oosterik when processing the necropsy samples.

Author details

¹Unit of Co-ordination in Veterinary Diagnostics-Epidemiology and Risk Analysis, CODA-CERVA, Groeselenberg 99, 1180 Ukkel, Belgium. ²Unit of Surveillance, Orientation and Veterinary Support, CODA-CERVA, Groeselenberg 99, 1180 Ukkel, Belgium. ³Unit of Bacteriology, CODA-CERVA, Groeselenberg 99, 1180 Ukkel, Belgium. ⁴Department of Obstetrics, Reproduction and Herd health, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820 Merelbeke, Belgium. ⁵Department of Pathology, Bacteriology and Avian diseases, Faculty of Veterinary Medicine, Ghent university, Salisburylaan 133, 9820 Merelbeke, Belgium. ⁶Department of Virology, parasitology and immunology, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820 Merelbeke, Belgium.

Received: 25 July 2013 Accepted: 27 November 2013

Published: 4 December 2013

References

1. EFSA, (European Food Safety Authority), ECDC (European Centre for Disease Prevention and Control): **The European Union Summary Report on Trends and Sources of Zoonoses, Zoonotic Agents and Food-borne Outbreaks in 2011.** *EFSA Journal* 2013, **11**(4):31–29.
2. Hotes S, Traulsen I, Krieter J: **Salmonella Control Measures with Special Focus on Vaccination and Logistic Slaughter Procedures.** *Transbound Emerg Dis* 2011, **58**(5):434–444.
3. Mannion C, Leonard FC, Lynch PB, Egan J: **Efficacy of cleaning and disinfection on pig farms in Ireland.** *Vet Rec* 2007, **161**(11):371–375.
4. Collard JM, Bertrand S, Dierick K, Godard C, Wildemauew C, Vermeersch K, Duculot J, Van Immerseel F, Pasmans F, Imberechts H, Quinet C: **Drastic decrease of Salmonella Enteritidis isolated from humans in Belgium in 2005, shift in phage types and influence on foodborne outbreaks.** *Epidemiol Infect* 2008, **136**(6):771–781.
5. EFSA, (European Food Safety Authority), ECDC (European Centre for Disease Prevention and Control): **The European Union Summary Report on Trends and Sources of Zoonoses, Zoonotic Agents and Food-borne Outbreaks in 2010.** *EFSA Journal* 2012, **10**(3):2597.
6. Roesler U, Marg H, Schroder I, Mauer S, Arnold T, Lehmann J, Truyen U, Hensel A: **Oral vaccination of pigs with an invasive gyrA-cpxA-rpoB Salmonella Typhimurium mutant.** *Vaccine* 2004, **23**(5):595–603.
7. Farzan A, Friendship RM: **A clinical field trial to evaluate the efficacy of vaccination in controlling Salmonella infection and the association of Salmonella-shedding and weight gain in pigs.** *Can J Vet Res* 2010, **74**(4):258–263.
8. De Ridder L, Maes D, Dewulf J, Pasmans F, Boyen F, Haesebrouck F, Meroc E, Butaye P, Van der Stede Y: **Evaluation of three intervention strategies to reduce the transmission of Salmonella Typhimurium in pigs.** *Vet J* 2013, **197**:613–618.
9. Abrahantes JC, Bollaerts K, Aerts M, Ogunsanya V, Van der Stede Y: **Salmonella serosurveillance: different statistical methods to categorise pig herds based on serological data.** *Prev Vet Med* 2009, **89**(1–2):59–66.
10. Selke M, Meens J, Springer S, Frank R, Gerlach GF: **Immunization of pigs to prevent disease in humans: construction and protective efficacy of a Salmonella enterica serovar Typhimurium live negative-marker vaccine.** *Infect Immun* 2007, **75**(5):2476–2483.
11. Leyman B, Boyen F, Van Parys A, Verbrugge E, Haesebrouck F, Pasmans F: **Salmonella Typhimurium LPS mutations for use in vaccines allowing differentiation of infected and vaccinated pigs.** *Vaccine* 2011, **29**(20):3679–3685.
12. Van Immerseel F, Boyen F, Gantois I, Timbermont L, Bohez L, Pasmans F, Haesebrouck F, Ducatelle R: **Supplementation of coated butyric acid in the feed reduces colonization and shedding of Salmonella in poultry.** *Poultry science* 2005, **84**(12):1851–1856.
13. Boyen F, Haesebrouck F, Vanparys A, Volf J, Mahu M, Van Immerseel F, Rychlik I, Dewulf J, Ducatelle R, Pasmans F: **Coated fatty acids alter virulence properties of Salmonella Typhimurium and decrease intestinal colonization of pigs.** *Vet Microbiol* 2008, **132**(3–4):319–327.
14. Guilloteau P, Martin L, Eeckhaut V, Ducatelle R, Zabielski R, Van Immerseel F: **From the gut to the peripheral tissues: the multiple effects of butyrate.** *Nutr Res Rev* 2010, **23**(2):366–384.
15. Boyen F, Pasmans F, Van Immerseel F, Morgan E, Botteldoorn N, Heyndrickx M, Volf J, Favoreel H, Hemalsteens JP, Ducatelle R, Haesebrouck F: **A limited role for SsrA/B in persistent Salmonella Typhimurium infections in pigs.** *Vet Microbiol* 2008, **128**(3–4):364–373.
16. ISO (International Organization of Standardization): **Detection of Salmonella spp. in animal feces and in environmental samples from the primary production stage.** In , Amendment ISO 6579:2002/Amd 1, (2007-07-04) Amendment 1 Annex D.
17. de Jong MCM, Diekmann O: **A method to calculate – for computer-simulated infections – the threshold value, R₀, that predicts whether or not the infection will spread.** *Prev Vet Med* 1992, **12**:269–285.
18. Meyns T, Maes D, Dewulf J, Vicca J, Haesebrouck F, de Kruijf A: **Quantification of the spread of Mycoplasma hyopneumoniae in nursery pigs using transmission experiments.** *Prev Vet Med* 2004, **66**(1–4):265–275.
19. Kroese AH, de Jong MCM: **Design and analysis of transmission experiments.** In *Proceedings of the Annual meeting of the Society for Veterinary Epidemiology and Preventive Medicine*, 28-30 March 2001; Noordwijkerhout; 2001:xxi–xxxvii.
20. Kearney J: **Food consumption trends and drivers.** *Philos Trans R Soc Lond B Biol Sci* 2010, **365**(1554):2793–2807.
21. Taube VA, Neu ME, Hassan Y, Verspohl J, Beyerbach M, Kamphues J: **Effects of dietary additives (potassium diformate/organic acids) as well as influences of grinding intensity (coarse/fine) of diets for weaned piglets experimentally infected with Salmonella Derby or Escherichia coli.** *J Anim Physiol An N* 2009, **93**(3):350–358.
22. Tanaka T, Imai Y, Kumagai N, Sato S: **The effect of feeding lactic acid to Salmonella Typhimurium experimentally infected swine.** *J Vet Med Sci* 2010, **72**(7):827–831.
23. Velthuis AG, De Jong MC, Kamp EM, Stockhofe N, Verheijden JH: **Design and analysis of an Actinobacillus pleuropneumoniae transmission experiment.** *Prev Vet Med* 2003, **60**(1):53–68.
24. Heres L, Urlings HA, Wagenaar JA, de Jong MC: **Transmission of Salmonella between broiler chickens fed with fermented liquid feed.** *Epidemiol Infect* 2004, **132**(1):107–116.
25. Dewulf J, Laevens H, Koenen F, Mintiens K, de Kruijf A: **Efficacy of E2-sub-unit marker and C-strain vaccines in reducing horizontal transmission of classical swine fever virus in weaner pigs.** *Prev Vet Med* 2004, **65**(3–4):121–133.
26. Bohez L, Dewulf J, Ducatelle R, Pasmans F, Haesebrouck F, Van Immerseel F: **The effect of oral administration of a homologous hilA mutant strain on the long-term colonization and transmission of Salmonella Enteritidis in broiler chickens.** *Vaccine* 2008, **26**(3):372–378.
27. Vrancken R, Haegeman A, Dewulf J, Paeshuyse J, Puerstinger G, Tignon M, Le Potier MF, Neyts J, Koenen F: **The reduction of CSFV transmission to untreated pigs by the pestivirus inhibitor BPIP: a proof of concept.** *Vet Microbiol* 2009, **139**(3–4):365–368.
28. Villarreal I, Maes D, Vranckx K, Calus D, Pasmans F, Haesebrouck F: **Effect of vaccination of pigs against experimental infection with high and low virulence Mycoplasma hyopneumoniae strains.** *Vaccine* 2011, **29**(9):1731–1735.
29. Crombé F, Vanderhaeghen W, Dewulf J, Hermans K, Haesebrouck F, Butaye P: **Colonization and transmission of methicillin-resistant**

- Staphylococcus aureus ST398 in nursery piglets. *Appl Environ Microbiol* 2012, **78**(5):1631–1634.
30. Claes G, Welby S, T VDB, Y VDS, Dewulf J, Lambrecht B, Marche S: **The impact of viral tropism and housing conditions on the transmission of three H5/H7 low pathogenic avian influenza viruses in chickens.** *Epidemiol Infect* 2013, **141**(11):2428–2443.
 31. van der Wolf PJ, van Schie FW, Elbers AR, Engel B, van der Heijden HM, Hunneman WA, Tielen MJ: **Administration of acidified drinking water to finishing pigs in order to prevent *Salmonella* infections.** *Vet Quart* 2001, **23**(3):121–125.
 32. Canibe N, Jensen BB: **Fermented and nonfermented liquid feed to growing pigs: effect on aspects of gastrointestinal ecology and growth performance.** *J Anim Sci* 2003, **81**(8):2019–2031.
 33. Springer S, Lindner T, Steinbach G, Selbitz HJ: **Investigation of the efficacy of a genetically-stabile live *Salmonella* Typhimurium vaccine for use in swine.** *Berl Munch Tierarztl* 2001, **114**(9–10):342–345.
 34. Hur J, Song SO, Lim JS, Chung IK, Lee JH: **Efficacy of a novel virulence gene-deleted *Salmonella* Typhimurium vaccine for protection against *Salmonella* infections in growing piglets.** *Vet Immunol Immunopathol* 2011, **139**(2–4):250–256.
 35. Creus E, Perez JF, Peralta B, Baucells F, Mateu E: **Effect of acidified feed on the prevalence of *Salmonella* in market-age pigs.** *Zoonoses Public Hlth* 2007, **54**(8):314–319.
 36. Walsh MC, Sholly DM, Saddoris KL, Aldridge BE, Sutton AL, Rostagno MH, Richert BT, Radcliffe JS: **A comparison of water delivered direct fed microbials or organic acids with in-feed antibiotics on weanling pig growth performance, intestinal morphology, gut microbiota and immune status following a *Salmonella* Typhimurium challenge.** *J Anim Sci* 2007, **85**:646–646.
 37. Martin-Pelaez S, Costabile A, Hoyles L, Rastall RA, Gibson GR, La Ragione RM, Woodward MJ, Mateu E, Martin-Orue SM: **Evaluation of the inclusion of a mixture of organic acids or lactulose into the feed of pigs experimentally challenged with *Salmonella* Typhimurium.** *Vet Microbiol* 2010, **142**(3–4):337–345.

doi:10.1186/1746-6148-9-243

Cite this article as: De Ridder et al.: Effect of a DIVA vaccine with and without in-feed use of coated calcium-butyrate on transmission of *Salmonella* Typhimurium in pigs. *BMC Veterinary Research* 2013 **9**:243.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

